SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3561 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2160<In addition to tonight Sanofi 2Q report, I think that next week is importantMiljenko Zuanic-7/31/2017
2159One small clarification from Bayer 2Q Eylea sale....smaller than expected growthMiljenko Zuanic-7/30/2017
2158It appears that Eylea will do well in 2Q, Roche Lucentis US sale for 2Q decline Miljenko Zuanic-7/27/2017
2157I hope so, however other than Eylea they don't have an approved product withFelix B-7/24/2017
2156Definitely, REGN and SNY are separating on R&D Abs future-collaborations. ThMiljenko Zuanic-7/20/2017
2155I continue to have hard time about perception (visualization) how big (or small)Miljenko Zuanic-7/18/2017
2154Cilic need to improve mental condition, if he want to play any rule...Miljenko Zuanic-7/17/2017
2153He'll be back. Though so might Federer....nigel bates-7/16/2017
2152Cilic was broken mentally, so his team was equally to blame for pure performanceMiljenko Zuanic17/16/2017
2151MZ, Last time it worked. Message 16044032 Sorry I failed to wish Cilic goodsmh17/16/2017
2150Refill rate for Dupi-rx suggest significant hurdle, so this story closely paint Miljenko Zuanic-7/15/2017
2149One year ago, Jack H. from Bernstein initiate REGN with Outperform (PT 410) baseMiljenko Zuanic-6/26/2017
2148<MZ- Any reason you can see for the roller coaster this week?> Jim, firstMiljenko Zuanic-6/23/2017
2147MZ- Any reason you can see for the roller coaster this week?Biotech Jim-6/23/2017
2146Also, keep in mind that REGN is working on PEG-Afliber formulation, but here I qMiljenko Zuanic-6/20/2017
2145ARVO 2017: arvo.org P# A0087.....overal, ~50% pts were on > or = Q12W, secoMiljenko Zuanic-6/20/2017
2144yan mentioned several time in last two Q-cc. Everyone knows, but pretend "bMiljenko Zuanic-6/20/2017
2143Curious why it's up, all the analysts seem to think this is a win for NovartFelix B-6/20/2017
2142novartis.com Not extraordinary, so far nothing BETTER, in the RTH258 results, aMiljenko Zuanic-6/20/2017
2141Ahhhh I meant fast trak the entire time, I can't keep track of all these FDAFelix B-6/18/2017
2140When did Tanezumab receive Breakthrough designation? It has fast track, which isMiljenko Zuanic-6/18/2017
2139So how can one get breakthrough and not the other is what I am asking? You woulFelix B-6/18/2017
2138It is a good article from ICER-corner, still missing deeper analysis of the drugMiljenko Zuanic-6/15/2017
2137They are not, I am talking about class compounds.Miljenko Zuanic-6/15/2017
2136How are they different?Felix B-6/15/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News